Skip to main content

Table 2 Patient, treatment and laboratory characteristics of patients with androgen deficiency and patients with normal androgen levels

From: Androgen deficiency in male patients diagnosed with ANCA-associated vasculitis: a cause of fatigue and reduced health-related quality of life?

Characteristics

Normal androgen levels

(number = 37)

Androgen deficiency (number = 33)

P

Age at study (years), mean (SD)

55 (13)

64 (10)

0.005

Diagnosis to study (months), median (IQR)

75 (39 to 119)

129 (70 to 168)

0.041

Last relapse to study (months), median (IQR)

36 (19 to 67)

49 (19 to 73)

0.403

BVAS = 0, n

37

33

 

VDI, median (IQR)

3 (2 to 4)

4 (2 to 5)

0.045

Cum. CY (g.), median (IQR)

22.4 (15.5 to 39.8)

46.6 (18.0 to 92.0)

0.049

Cum. GC (g.), median (IQR)

10.6 (6.1 to 18.4)

21.7 (13.5 to 33.0)

0.001

TT (nmol/L), mean (SD)

17.4 (5.5)

9.8 (1.9)

<0.001

FT (pmol/L), mean (SD)

313 (103)

193 (51)

<0.001

SHBG (nmol/L), mean (SD)

43 (12)

35 (15)

0.029

Hb (mmol/L), mean (SD)

9.0 (1.0)

8.4 (0.9)

0.009

CRP (mg/L), median (IQR)

<5 (<5 to <5)

<5 (<5 to 9)

0.072

CC (ml/min), mean (SD)

91 (27)

89 (39)

0.811

Treatment at study

   

No treatment, number

11

7

 

CT, number

9

5

 

GC (+ CT), number

3 (1)

7 (2)

 

Aza (+CT), number

8 (6)

2 (1)

 

MMF (+CT), number

3 (3)

2 (1)

 

GC and Aza (+CT), number

1 (1)

6 (6)

 

GC and MMF (+CT), number

2 (2)

4 (3)

 
  1. Aza, azathioprine; BVAS, Birmingham Vasculitis Activity Score; CC, creatinine clearance; CRP, C-reactive protein; CT, co-trimoxazole, 2 dd 800/160 mg; Cum. CY, cumulative cyclophosphamide; Cum. GC, cumulative glucocorticoid; FT, free testosterone; Hb, hemoglobin; MMF, mycophenolate mofetil; SHBG, sex hormone-binding globulin; TT, total testosterone; VDI, Vasculitis Damage Index.